Abstract
Arsenic trioxide (As2O3) induces cell apoptosis and reduces the invasive and metastatic activities in various cancer types. However, the role of As2O3 in ovarian cancer angiogenesis remains unclear. In this study, we investigated the role of As2O3 in ovarian cancer angiogenesis and found that a low concentration of As2O3 causes no effects on epithelial ovarian cancer cell viability or apoptosis. Moreover, we found that As2O3-treated epithelial ovarian cancer cells demonstrate a reduced tube formation of endothelial cells in Matrigel. In addition, As2O3-treated epithelial ovarian cancer cells show a decreased VEGFA, VEGFR2 and CD31 mRNA expression. As per the underlying mechanisms involved in As2O3 treatment, we found that As2O3 inhibits VEGFA and VEGFR2 expression that thereby inhibits the VEGFA–VEGFR2–PI3K/ERK signaling pathway. This leads to a suppression in both VEGFA synthesis and angiogenesis-related gene expression. A decreased VEGFA synthesis and secretion also inhibits the VEGFA–VEGFR2–PI3K/ERK signaling pathway in human umbilical vein endothelial cells (HUVECs). In summary, our results may provide strategies for the use of As2O3 in the prevention of tumor angiogenesis.
Similar content being viewed by others
References
Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
Niu H, Zhou W, Xu Y, Yin Z, Shen W, Ye Z, Liu Y, Chen Y, Yang S, Xiang R, Wang L, Qu P (2017) Silencing PPA1 inhibits human epithelial ovarian cancer metastasis by suppressing the Wnt/beta-catenin signaling pathway. Oncotarget 8:76266–76278
Bookman MA (2013) Should studies of maintenance therapy be maintained in women with ovarian cancer? J Gynecol Oncol 24:105–107
Chen Y, Zhang L, Liu WX, Wang K (2018) VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Cell Mol Biol Lett 23:2
Folkman J (2000) Incipient angiogenesis. J Natl Cancer Inst 92:94–95
Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133:275–288
Gianni-Barrera R, Trani M, Reginato S, Banfi A (2011) To sprout or to split? VEGF, Notch and vascular morphogenesis. Biochem Soc Trans 39:1644–1648
Scartozzi M, Faloppi L, Svegliati Baroni G, Loretelli C, Piscaglia F, Iavarone M, Toniutto P, Fava G, De Minicis S, Mandolesi A, Bianconi M, Giampieri R, Granito A, Facchetti F, Bitetto D, Marinelli S, Venerandi L, Vavassori S, Gemini S, D’Errico A, Colombo M, Bolondi L, Bearzi I, Benedetti A, Cascinu S (2014) VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer (Journal international du cancer) 135:1247–1256
Zhang Y, Zhang Z, Li J, Li L, Han X, Han L, Hu L, Wang S, Zhao Y, Li X, Zhang Y, Fan S, Lv C, Li Y, Su Y, Zhao H, Zhang X, Zhou J (2013) Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer 119:115–125
Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189:1043–1052
Pettersson HM, Pietras A, Munksgaard Persson M, Karlsson J, Johansson L, Shoshan MC, Pahlman S (2009) Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells. Mol Cancer Ther 8:160–170
Yu J, Qian H, Li Y, Wang Y, Zhang X, Liang X, Fu M, Lin C (2007) Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol 106:400–406
Ma ZB, Xu HY, Jiang M, Yang YL, Liu LX, Li YH (2014) Arsenic trioxide induces apoptosis of human gastrointestinal cancer cells. World J Gastroenterol 20:5505–5510
Alarifi S, Ali D, Alkahtani S, Siddiqui MA, Ali BA (2013) Arsenic trioxide-mediated oxidative stress and genotoxicity in human hepatocellular carcinoma cells. Oncotargets Ther 6:75–84
Shen W, Xie J, Zhao S, Du R, Luo X, He H, Jiang S, Hao N, Chen C, Guo C, Liu Y, Chen Y, Sun P, Yang S, Luo N, Xiang R, Luo Y (2018) ICAM3 mediates inflammatory signaling to promote cancer cell stemness. Cancer Lett 422:29–43
Shen W, Chang A, Wang J, Zhou W, Gao R, Li J, Xu Y, Luo X, Xiang R, Luo N, Stupack DG (2015) TIFA, an inflammatory signaling adaptor, is tumor suppressive for liver cancer. Oncogenesis 4:e173
Shen W, Zhang X, Du R, Fan Y, Luo D, Bao Y, Yang W, Luo N, Luo Y, Zhao S (2018) ICAM3 mediates tumor metastasis via a LFA-1-ICAM3-ERM dependent manner. Biochimica et Biophysica Acta (BBA) Mol Basis Dis 1864:2566–2578
Shen W, Du R, Li J, Luo X, Zhao S, Chang A, Zhou W, Gao R, Luo D, Wang J, Hao N, Liu Y, Chen Y, Luo Y, Sun P, Yang S, Luo N, Xiang R (2016) TIFA suppresses hepatocellular carcinoma progression via MALT1-dependent and -independent signaling pathways. Signal Transduct Target Ther 1:16013
Shen L, Li H, Shi Y, Wang D, Gong J, Xun J, Zhou S, Xiang R, Tan X (2016) M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma. Sci Rep 6:30347
Zhao S, Shen W, Yu J, Wang L (2018) TBX21 predicts prognosis of patients and drives cancer stem cell maintenance via the TBX21-IL-4 pathway in lung adenocarcinoma. Stem Cell Res Ther 9:89
Chen SJ, Zhou GB, Zhang XW, Mao JH, de The H, Chen Z (2011) From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia. Blood 117:6425–6437
Zhang X, Jia S, Yang S, Yang Y, Yang T, Yang Y (2012) Arsenic trioxide induces G2/M arrest in hepatocellular carcinoma cells by increasing the tumor suppressor PTEN expression. J Cell Biochem 113:3528–3535
Gao JK, Wang LX, Long B, Ye XT, Su JN, Yin XY, Zhou XX, Wang ZW (2015) Arsenic trioxide inhibits cell growth and invasion via down-regulation of Skp2 in pancreatic cancer cells. Asian Pac J Cancer Prev APJCP 16:3805–3810
Ji H, Li Y, Jiang F, Wang X, Zhang J, Shen J, Yang X (2014) Inhibition of transforming growth factor beta/SMAD signal by MiR-155 is involved in arsenic trioxide-induced anti-angiogenesis in prostate cancer. Cancer Sci 105:1541–1549
Wang H, Gao P, Zheng J (2014) Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells. Biochem Biophys Res Commun 451:556–561
Jiang F, Wang X, Liu Q, Shen J, Li Z, Li Y, Zhang J (2014) Inhibition of TGF-beta/SMAD3/NF-kappaB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells. Toxicol Lett 231:55–61
Xiao YF, Wu DD, Liu SX, Chen X, Ren LF (2007) Effect of arsenic trioxide on vascular endothelial cell proliferation and expression of vascular endothelial growth factor receptors Flt-1 and KDR in gastric cancer in nude mice. World J Gastroenterol 13:6498–6505
Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17:1359–1370
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2:737–744
Deryugina EI, Quigley JP (1803) Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochem Biophys Acta 2010:103–120
Sakurai T, Kudo M (2011) Signaling pathways governing tumor angiogenesis. Oncology 81(Suppl 1):24–29
Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312
Lohela M, Bry M, Tammela T, Alitalo K (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21:154–165
Cao Y, Cao R, Hedlund EM (2008) R regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berlin, Germany) 86:785–789
Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G (2006) Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444:1032–1037
Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G, Yan M (2006) Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444:1083–1087
Funding
This work was supported by Faculty Start-up Funds of Jining Medical University (No. 600640001 to W Shen.), Shandong Medical Science and Technology Program (No. 2017WS144 to W Shen.) and Guizhou Traditional Chinese Medicine & National Medicine Science and Technology Research Program (No. QZYY2017-20 to D Luo).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interests
The authors declare no potential conflicts of interest.
Rights and permissions
About this article
Cite this article
Luo, D., Zhang, X., Du, R. et al. Low dosage of arsenic trioxide (As2O3) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis. J Biol Inorg Chem 23, 939–947 (2018). https://doi.org/10.1007/s00775-018-1595-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00775-018-1595-z